Savara (SVRA) Other Working Capital Changes (2010 - 2026)
Savara (SVRA) posted quarterly Other Working Capital Changes of $639000.0 for Q1 2026, up 174.39% year-over-year from $232881.2 in Q1 2025, and down 72.85% quarter-over-quarter from $2.4 million in Q4 2025.
Analysis
Savara (SVRA) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Other Working Capital Changes for 17 consecutive years, with $639000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 174.39% year-over-year to $639000.0; the TTM figure through Mar 2026 stood at $1.4 million (down 20.71% YoY), while the FY2025 annual figure was -$97000.0, down 104.07% from the prior year.
- Other Working Capital Changes fell to $639000.0 in Q1 2026 per SVRA's latest filing, from $2.4 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $2.9 million in Q2 2024 and bottomed at -$1.6 million in Q1 2022.
- Historically, Other Working Capital Changes has averaged $120294.1 across 5 years, with a median of -$116000.0 in 2023.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes plunged 1056.25% — and 2024, when it jumped 2617.24%.
- Savara's Other Working Capital Changes stood at -$79000.0 in 2022, then surged by 2122.78% to $1.6 million in 2023, then tumbled by 160.95% to -$974000.0 in 2024, then soared by 341.68% to $2.4 million in 2025, then tumbled by 72.85% to $639000.0 in 2026.
- Business Quant data shows SVRA's Other Working Capital Changes at $639000.0 in Q1 2026, $2.4 million in Q4 2025, and -$712000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Mn |
| Jun 30, 2026 | -1.48 Mn |
| Mar 31, 2026 | 639,000.00 |
| Mar 31, 2026 | 639,000.00 |
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | -712,000.00 |
| Sep 30, 2025 | -712,000.00 |
| Jun 30, 2025 | -880,000.00 |
| Jun 30, 2025 | -880,000.00 |
| Mar 31, 2025 | -859,000.00 |
| Mar 31, 2025 | -859,000.00 |
| Dec 31, 2024 | -974,000.00 |
| Dec 31, 2024 | -974,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | -243,000.00 |
| Mar 31, 2024 | -243,000.00 |